Larysa Kuts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Larysa Kuts has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Nadiia Demikhova
Sumy State University, Sumy, Ukraine; Tallinn University of Technology, Tallinn, Estonia
2 shared publications - Ahmed El Gohary
King Fahd Specialist Hospital, Tabuk, Saudi Arabia
1 shared publication - Daniela Koleva-Tyutyundzhieva
Medical University of Plovdiv, Plovdiv, Bulgaria
1 shared publication - Eda Merisalu
Estonian University of Life Sciences, Tartu, Estonia
1 shared publication - Iia Dehtiarova
Dnipro Institute of Medicine and Public Health, Ukraine
1 shared publication - Jamol Uzokov
Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Tashkent, Uzbekistan
1 shared publication
Latest Publications
- Open Access
- 24 February 2026
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 1(89),p. 54-65
Nephrotic syndrome: Management of dyslipidemia, pathophysiological insights, and therapeutic perspectives
Dyslipidemia is a characteristic feature of nephrotic syndrome (NS), which significantly increases the risk of cardiovascular complications and progression of chronic kidney disease. This review analyzes current understanding of the complex pathophysiological mechanisms of lipid metabolism disorders in NS. Particular attention is paid to the impact of proteinuria on the synthesis of lipoproteins by the liver and impaired clearance. The article systematizes current therapeutic strategies. Therapeutic prospects aimed at correcting the lipid profile as a means of nephroprotection are considered. The review emphasizes the need for a personalized approach to the management of dyslipidemia, taking into account the etiology of NS and the functional state of the kidneys.
- 24 February 2026
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 1(89),p. 54-65
Open AccessNephrotic syndrome: Management of dyslipidemia, pathophysiological insights, and therapeutic perspectives
Dyslipidemia is a characteristic feature of nephrotic syndrome (NS), which significantly increases the risk of cardiovascular complications and progression of chronic kidney disease. This review analyzes current understanding of the complex pathophysiological mechanisms of lipid metabolism disorders in NS. Particular attention is paid to the impact of proteinuria on the synthesis of lipoproteins by the liver and impaired clearance. The article systematizes current therapeutic strategies. Therapeutic prospects aimed at correcting the lipid profile as a means of nephroprotection are considered. The review emphasizes the need for a personalized approach to the management of dyslipidemia, taking into account the etiology of NS and the functional state of the kidneys.
- Open Access
- 17 May 2025
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 2(86),p. 90-97
Diagnostic and therapeutic potential of interleukin-37 in kidney diseases: A mini-review
Interleukin-37 (IL-37) is a newly discovered anti-inflammatory cytokine from the IL-1 family that plays a key role in regulating both innate and adaptive immune responses. It is secreted in healthy tissues, reflecting a homeostatic function. Intracellularly, IL-37 suppresses diverse inflammatory signals in various cells, including dendritic cells, macrophages, epithelial cells, and endothelial cells. Although it has been studied in many conditions, such as autoimmune disorders, cancer, and cardiovascular disease, its specific role in kidney diseases remains relatively understudied. In this mini-review, we summarize current evidence on the biology of IL-37, with a focus on its relevance to kidney disease. We explore its molecular structure, patterns of expression, and the immunomodulatory mechanisms that may influence kidney diseases, including acute kidney injury, diabetic nephropathy, and autosomal dominant polycystic kidney disease. We also discuss the challenges of translating IL-37-based therapies into clinical practice and highlight key areas for future research aimed at unlocking its potential in the treatment of kidney diseases.
- 17 May 2025
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 2(86),p. 90-97
Open AccessDiagnostic and therapeutic potential of interleukin-37 in kidney diseases: A mini-review
Interleukin-37 (IL-37) is a newly discovered anti-inflammatory cytokine from the IL-1 family that plays a key role in regulating both innate and adaptive immune responses. It is secreted in healthy tissues, reflecting a homeostatic function. Intracellularly, IL-37 suppresses diverse inflammatory signals in various cells, including dendritic cells, macrophages, epithelial cells, and endothelial cells. Although it has been studied in many conditions, such as autoimmune disorders, cancer, and cardiovascular disease, its specific role in kidney diseases remains relatively understudied. In this mini-review, we summarize current evidence on the biology of IL-37, with a focus on its relevance to kidney disease. We explore its molecular structure, patterns of expression, and the immunomodulatory mechanisms that may influence kidney diseases, including acute kidney injury, diabetic nephropathy, and autosomal dominant polycystic kidney disease. We also discuss the challenges of translating IL-37-based therapies into clinical practice and highlight key areas for future research aimed at unlocking its potential in the treatment of kidney diseases.